A One Year, Open Label, Multicenter Trial of LBH589 Alone or in Combination With ESA in Red Blood Cell Transfusion-dependent LOW and INT-1 MDS Patients Being Either Refractory to ESA or With a Low Probability of Response - the GErman PAnobinostat Low Risk MDS Trial - GEPARD Study.

Trial Profile

A One Year, Open Label, Multicenter Trial of LBH589 Alone or in Combination With ESA in Red Blood Cell Transfusion-dependent LOW and INT-1 MDS Patients Being Either Refractory to ESA or With a Low Probability of Response - the GErman PAnobinostat Low Risk MDS Trial - GEPARD Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Panobinostat (Primary) ; Epoetin alfa
  • Indications Myelodysplastic syndromes
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms GEPARD
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Oct 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003820).
    • 31 May 2012 Planned end date changed from 1 Nov 2011 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top